Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Acer Therapeutics Inc. | opxa_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 2,
2017
ACER THERAPEUTICS INC.
(Exact
name of registrant as specified in its charter)
|
Texas
|
|
001-33004
|
|
76-0333165
|
|
(State
or other jurisdiction ofincorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
222 Third Street, Suite #2240, Cambridge,
Massachusetts
|
|
02142
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
||
|
Registrant’s
telephone number, including area code: (844) 902-6100
|
||
|
N/A
|
||
|
(Former
name or former address, if changed since last report)
|
||
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item
5.02. Departure of Directors or
Certain Officers; Election of Directors, Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
Acer
Therapeutics Inc. (the “Company”) appointed William T.
Andrews, M.D., FACP as Chief Medical Officer of the Company as of
October 2, 2017 to succeed Robert D. Steiner, M.D. in that
position.
Item
7.01 Regulation FD
Disclosure.
A copy
of the press release issued by the Company on October 5, 2017 is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item
9.01. Financial Statements and
Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
Press
release issued by Acer Therapeutics Inc. on October 5,
2017.
|
The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities under that Section, nor be
deemed to be incorporated by reference into the filings of the
registrant under the Securities Act of 1933.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| Dated: October 5, 2017 |
ACER THERAPEUTICS
INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Harry S.
Palmin
|
|
|
|
|
Harry S.
Palmin
|
|
|
|
|
Chief
Financial Officer
|
|